These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 12091059)
1. Diagnostic advances and new trends for the treatment of primary central nervous system lymphoma. Basso U; Brandes AA Eur J Cancer; 2002 Jul; 38(10):1298-312. PubMed ID: 12091059 [TBL] [Abstract][Full Text] [Related]
2. Advances for the treatment of primary central nervous system lymphoma (review). Yamanaka R; Tanaka R Oncol Rep; 2004 Sep; 12(3):563-8. PubMed ID: 15289838 [TBL] [Abstract][Full Text] [Related]
3. Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy. Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T; Fukushima T J Neurooncol; 2003 May; 63(1):87-95. PubMed ID: 12814260 [TBL] [Abstract][Full Text] [Related]
4. [Therapeutic management of central nervous system lymphomas in a single hematological institute]. Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012 [TBL] [Abstract][Full Text] [Related]
8. Advances and challenges in the treatment of primary central nervous system lymphoma. Yang H; Xun Y; Yang A; Liu F; You H J Cell Physiol; 2020 Dec; 235(12):9143-9165. PubMed ID: 32420657 [TBL] [Abstract][Full Text] [Related]
9. Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome. Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu G; Lokesh KN; Rajeev LK J Cancer Res Ther; 2020; 16(1):13-17. PubMed ID: 32362603 [TBL] [Abstract][Full Text] [Related]
10. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL). Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274 [TBL] [Abstract][Full Text] [Related]
11. Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy. Korfel A; Thiel E Leuk Lymphoma; 1998 Aug; 30(5-6):609-17. PubMed ID: 9711923 [TBL] [Abstract][Full Text] [Related]
12. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169 [TBL] [Abstract][Full Text] [Related]
13. CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma. Bessell EM; Graus F; López-Guillermo A; Villá S; Verger E; Petit J; Holland I; Byrne P Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):457-64. PubMed ID: 11380234 [TBL] [Abstract][Full Text] [Related]
14. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome. Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112 [TBL] [Abstract][Full Text] [Related]
15. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Ferreri AJ; Reni M; Foppoli M; Martelli M; Pangalis GA; Frezzato M; Cabras MG; Fabbri A; Corazzelli G; Ilariucci F; Rossi G; Soffietti R; Stelitano C; Vallisa D; Zaja F; Zoppegno L; Aondio GM; Avvisati G; Balzarotti M; Brandes AA; Fajardo J; Gomez H; Guarini A; Pinotti G; Rigacci L; Uhlmann C; Picozzi P; Vezzulli P; Ponzoni M; Zucca E; Caligaris-Cappio F; Cavalli F; Lancet; 2009 Oct; 374(9700):1512-20. PubMed ID: 19767089 [TBL] [Abstract][Full Text] [Related]